Educational Programmes

Current opinions on how to identify and treat NTRK fusion positive cancer
We recently delivered a virtual Experts Knowledge Share meeting discussing the Current opinions on how to identify, test and treat NTRK fusion positive cancer. Our faculty of international experts Prof. David Hong (USA), Prof. Frédérique Penault-Llorca (France), and Prof. Ezra Cohen (USA), were joined by participants from over 20 countries across the world. The slides from this meeting are now available for download.
read more










NTRK CONNECT provides an overview of the occurrence of NTRK fusions and TRK inhibitor therapy in GI cancer
Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED
read more










Learn about the patient journey through diagnosis and treatment of NTRK fusion positive cancer
Watch this video to better understand the paths for solid tumour that are low and high prevalence for NTRK fusions, emphasising predictors that can inform an enrichment strategy in the diagnostic process.
read more










Key Publication Snapshot 5: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
NTRK CONNECT’s Key Publication Snapshot 5 is now available: This fifth Publication Snapshot in the series provides insights into on-target resistance to next-generation TRK inhibitors in NTRK fusion positive cancers.
read more










Key Publication Snapshot 4: Diagnosis and management of NTRK fusion positive sarcomas – recommendations from the World Sarcoma Network
NTRK CONNECT’s Key Publication Snapshot 4 is now available: Diagnosis and management of NTRK fusion positive sarcomas – recommendations from the World Sarcoma Network
read more










Key Publication Snapshot 3 – Characterisation of adverse events caused by TRK inhibitor therapy
NTRK CONNECT’s Key Publication Snapshot 3 is now available. How familiar are you with the common adverse events seen with TRK inhibitor therapy?
read more










Key Publication Snapshot 2 – Identifying patients with NTRK fusion cancer
NTRK CONNECT’s Key Publication Snapshot 2 is now available. How familiar are you with the range of testing approaches to identify patients with NTRK fusion cancer?
read more










Key Publication Snapshot 1 – Larotrectinib and Entrectinib efficacy and safety profile in solid tumours
NTRK CONNECT’s Key Publication Snapshot 1 is now available. What do we know in 2020 about the two approved TRK inhibitors Larotrectinib and Entrectinib?
read more










Molecular subtypes in paediatric and adult sarcomas, including CIC-DUX4, NTRK gene fusions and SDH-deficient GIST
NTRK CONNECT have partnered with SARCOMA CONNECT to describe a number of the molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions.
read more










NTRK gene fusions, TRK inhibitors and testing approaches BluePrint
NTRK CONNECT identified NTRK Gene Fusions on the ESMO OncologyPro portal as a practical guide on how to test for NTRK gene fusions and treat with TRK inhibitors.
read more



NTRK CONNECT Update from ESMO 2020
NTRK CONNECT has summarised the highlights from ESMO 2020 for you
read more



NTRK CONNECT Update from ASCO 2020
NTRK CONNECT has summarised the highlights from ASCO 2020 for you.
read more



NTRK CONNECT Update from ESMO 2019
NTRK CONNECT has summarised highlights of the recent ESMO 2019 meeting for you.
read morePlease submit your clinical topic for the next NTRK CONNECT newsletter here.